Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“”Immusoft””), a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced positive results from the Phase 1 ISP-001 trial evaluating the therapy in a patient with mucopolysaccharidosis type I (MPS I). The clinical trial is supported by an $8 million award from the California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutes dedicated to regenerative medicine. “”Although the Phase 1 focus is safety, we have observed activity and functional improvements, even at the low dose, far beyond our initial expectations, and are very excited by this data,”” said Sean Ainsworth, Immusoft Chief Executive Officer. Read more >>